Novavax Global Commercial Operations and COVID-19 Vaccine Update

Near-term priorities to support success Priority #1 Deliver a competitive product for the upcoming 2023 fall vaccination season Priority #2 Reduce our rate of spend, manage our cash flow, and evolve our scale & structure Priority #3 Leverage our technology platform, our capabilities, and our portfolio of assets to drive additional value beyond Nuvaxovid¹ alone novavax: 1. The trade name Nuvaxovid has not yet been approved by the FDA. © 2023 NOVAVAX. All rights reserved. 13

View entire presentation